We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

154 hedge funds and large institutions have $427M invested in BioCryst Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 43 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 43

5% less call options, than puts

Call options by funds: $4.4M | Put options by funds: $4.64M

3.24% less ownership

Funds ownership: 75.5% → 72.26% (-3.2%)

7% less funds holding

Funds holding: 165 → 154 (-11)

29% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 35

33% less capital invested

Capital invested by funds: $635M → $427M (-$208M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
154
Holders Change
-11
Holders Change %
-6.67%
% of All Funds
3.11%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
25
Increased
62
Reduced
43
Closed
35
Calls
$4.4M
Puts
$4.64M
Net Calls
-$237K
Net Calls Change
-$8.12M

Top Buyers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
+$16.2M
2
UBS Group
UBS Group
Switzerland
+$5.48M
3
BlackRock
BlackRock
New York
+$5.47M
4
Victory Capital Management
Victory Capital Management
Texas
+$3.89M
5
State Street
State Street
Massachusetts
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
EP
Eversept Partners
New York
-$15.9M
2
Millennium Management
Millennium Management
New York
-$13.6M
3
ACP
Acuta Capital Partners
California
-$5.31M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.96M
5
BBA
Baker Bros. Advisors
New York
-$4.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
26
Eversept Partners
New York
$3.93M -$15.9M -3,704,581 -76%
Norges Bank
27
Norges Bank
Norway
$3.54M +$2.09M +488,600 +90%
WP
28
Woodline Partners
California
$2.98M -$3.09M -722,133 -45%
Bank of America
29
Bank of America
North Carolina
$2.95M -$3.99M -932,049 -52%
PHP
30
Parkman Healthcare Partners
Connecticut
$2.75M -$428K -99,868 -11%
SI
31
Sofinnova Investments
California
$2.73M -$2.42M -564,794 -42%
DCM
32
DAFNA Capital Management
California
$2.57M +$21.4K +5,000 +0.7%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.5M -$448K -104,484 -13%
PVI
34
Pura Vida Investments
New York
$2.48M +$1.22M +285,419 +65%
ACP
35
Acuta Capital Partners
California
$2.27M -$5.31M -1,240,000 -65%
Point72 Asset Management
36
Point72 Asset Management
Connecticut
$2.17M -$1.09M -254,970 -29%
GGHC
37
Gilder Gagnon Howe & Co
New York
$2.03M +$2.54M +592,200 New
FAM
38
Formidable Asset Management
Ohio
$1.95M -$93.4K -21,800 -4%
Verition Fund Management
39
Verition Fund Management
Connecticut
$1.86M +$2.32M +541,839 New
Rafferty Asset Management
40
Rafferty Asset Management
New York
$1.81M +$1.3M +303,685 +136%
Wells Fargo
41
Wells Fargo
California
$1.61M -$49K -11,436 -2%
PIM
42
Platinum Investment Management
Australia
$1.59M – – –
TRCT
43
Tower Research Capital (TRC)
New York
$1.52M +$1.47M +343,144 +341%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$1.37M +$229K +53,342 +15%
DMK
45
David M. Knott
$1.36M – – –
Swiss National Bank
46
Swiss National Bank
Switzerland
$1.35M +$28.3K +6,600 +2%
State of Wisconsin Investment Board
47
State of Wisconsin Investment Board
Wisconsin
$1.17M +$472K +110,100 +48%
Barclays
48
Barclays
United Kingdom
$987K -$369K -86,006 -23%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$918K +$143K +33,309 +14%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$912K -$46.1K -10,754 -4%
1
2
3 4 5

BCRX Hedge Fund Activity: Q3 2020 in Review

154 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2020, worth a combined $427M — down 33% from $635M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of BCRX and 25 opened new positions — a net loss of 10 holders — while 43 trimmed existing stakes and 62 added.

The largest buyer was Sarissa Capital Management, adding an estimated $16.2M. The largest seller was Eversept Partners, cutting an estimated $15.9M.

  • 154 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2020, down from 165 in Q2 2020.
  • Funds reported $427M of BioCryst Pharmaceuticals stock for Q3 2020, down 33% quarter-over-quarter.
  • 25 funds opened new BioCryst Pharmaceuticals positions in Q3 2020 and 35 closed out, a net change of -10 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2020 was Sarissa Capital Management, an estimated $16.2M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2020 was Eversept Partners, an estimated $15.9M sold.

Based on aggregated 13F filings for Q3 2020.